Rubius Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Liquidation

Rubius Therapeutics General Information

Description

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 399 Binney Street
  • Suite 300
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Discovery
Other Industries
Therapeutic Devices
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 399 Binney Street
  • Suite 300
  • Cambridge, MA 02139
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rubius Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Bankruptcy: Liquidation 06-Apr-2023 Completed Bankruptcy: Liquidation
6. Debt Refinancing 21-Dec-2018 Completed Pre-Clinical Trials
5. IPO 18-Jul-2018 Completed Pre-Clinical Trials
4. Later Stage VC (Series C) 01-Mar-2018 Completed Generating Revenue
3. Early Stage VC (Series B) 21-Jun-2017 Completed Generating Revenue
2. Early Stage VC (Series A) 27-Dec-2016 $25M $25M Completed Generating Revenue
1. Debt - General 01-Nov-2015 Completed Generating Revenue
To view Rubius Therapeutics’s complete valuation and funding history, request access »

Rubius Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 29,703,995 $0.001000 8% $0.6 $0.6 1x $0.6 39.94%
To view Rubius Therapeutics’s complete cap table history, request access »

Rubius Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer,
Drug Discovery
Cambridge, MA
6 As of 2022

Lyon, France
 

Santa Monica, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Rubius Therapeutics Competitors (21)

One of Rubius Therapeutics’s 21 competitors is PHAXIAM Therapeutics, a Formerly VC-backed company based in Lyon, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PHAXIAM Therapeutics Formerly VC-backed Lyon, France
Kite Pharma Formerly VC-backed Santa Monica, CA
American Gene Technologies Venture Capital-Backed Rockville, MD
Anokion Venture Capital-Backed Ecublens, Switzerland
Mustang Bio Formerly VC-backed Worcester, MA
You’re viewing 5 of 21 competitors. Get the full list »

Rubius Therapeutics Patents

Rubius Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210246426-A1 Engineered erythroid cells including hla-g polypeptides and methods of use thereof Inactive 10-Feb-2020
EP-4103696-A1 Engineered erythroid cells including hla-g polypeptides and methods of use thereof Inactive 10-Feb-2020
US-20210147802-A1 Methods of generating enucleated erythroid cells using taurine or hypotaurine Inactive 04-Nov-2019
US-20210130780-A1 Methods of generating enucleated erythroid cells using myo-inositol Inactive 04-Nov-2019
AU-2020379755-A1 Methods of generating enucleated erythroid cells using myo-inositol Inactive 04-Nov-2019 C12N5/0641
To view Rubius Therapeutics’s complete patent history, request access »

Rubius Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rubius Therapeutics Investments (2)

Rubius Therapeutics’s most recent deal was a Corporate Asset Purchase with 135,000-square foot manufacturing facility in Rhode Island for . The deal was made on 31-Jul-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
135,000-square foot manufacturing facility in Rhode Island 31-Jul-2018 Corporate Asset Purchase Buildings and Property
100 Technology Way, Smithfield, Rhode Island 01-Jul-2018 Corporate Asset Purchase Buildings and Property
To view Rubius Therapeutics’s complete investments history, request access »

Rubius Therapeutics ESG

Risk Overview

Risk Rating

Updated October, 07, 2022

28.05 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,638

Rank

Percentile

Pharmaceuticals

Industry

of 1,008

Rank

Percentile

Biotechnology

Subindustry

of 465

Rank

Percentile

To view Rubius Therapeutics’s complete esg history, request access »

Rubius Therapeutics FAQs

  • When was Rubius Therapeutics founded?

    Rubius Therapeutics was founded in 2013.

  • Where is Rubius Therapeutics headquartered?

    Rubius Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Rubius Therapeutics?

    Rubius Therapeutics has 6 total employees.

  • What industry is Rubius Therapeutics in?

    Rubius Therapeutics’s primary industry is Drug Discovery.

  • Is Rubius Therapeutics a private or public company?

    Rubius Therapeutics is a Private company.

  • What is Rubius Therapeutics’s current revenue?

    The current revenue for Rubius Therapeutics is .

  • How much funding has Rubius Therapeutics raised over time?

    Rubius Therapeutics has raised $562M.

  • Who are Rubius Therapeutics’s competitors?

    PHAXIAM Therapeutics, Kite Pharma, American Gene Technologies, Anokion, and Mustang Bio are some of the 21 competitors of Rubius Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »